Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 439-447

  Pocobelli, Gaia ^a,d   Newcomb, Polly A ^a,b   Li, Christopher I ^a,b   Cook, Linda S ^c   Barlow, William E ^a,b,d   Weiss, Noel S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Estrogen; Menopause; Mortality; Progestin

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DATABASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; ADVERSE EFFECTS; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED; EPIDEMIOLOGY; ESTROGEN THERAPY; MIDDLE AGED; MORTALITY; ODDS RATIO; RISK FACTOR; SASKATCHEWAN;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SASKATCHEWAN;

EID: 84901691644     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2911-0     Document Type: Article

References (27)

1. Collins J, Blake J, Crosignani P (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11(6):545-560 (Pubitemid 41631306)
2. Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: A systematic review and meta-analysis. Menopause 12(6):668-678 (Pubitemid 41669118)
3. Norman SA, Weber AL, Localio AR, Marchbanks PA, Ursin G, Strom BL, Weiss LK, Burkman RT, Bernstein L, Deapen DM et al (2010) Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 19(5):440-447
4. Chlebowski R, Hendrix S, Langer R, Stefanick M, Gass M, Lane D, Rodabough R, Gilligan M, Cyr M, Thomson C et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289(24):3243-3253 (Pubitemid 37430077)
5. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684-1692
6. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C et al (2013) Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 105(8):526-535
7. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D et al (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13(5):476-486
8. Downey W, Strang M, Beck P, Osei W, Nichol JL (2005) Health services databases in Saskatchewan. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 295-310
9. World Health Organization (1977) Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, 9th revision. WHO, Geneva
10. World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 10th revision. WHO, Geneva
11. Edouard L, Eberts L, Baldwin J (1994) A population-based screening mammography program in Saskatchewan. Am J Public Health 84(6):1030-1031
12. Saskatchewan Cancer Agency. Screening Program for Breast Cancer. http://www.saskcancer.ca/Default.aspx?DN=80e4bb14-ed7d-4f79-852f-3316d42de414. Accessed 15 Oct 2012
13. Nichols HB, Visvanathan K, Newcomb PA, Hampton JM, Egan KM, Titus-Ernstoff L, Trentham-Dietz A (2011) Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery? Am J Epidemiol 173(10):1111-1120
14. Press DJ, Sullivan-Halley J, Ursin G, Deapen D, McDonald JA, Strom BL, Norman SA, Simon MS, Marchbanks PA, Folger SG et al (2011) Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences study. Am J Epidemiol 173(1):38-47
15. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J et al (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170(1):12-23
16. Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67(3):327-332 (Pubitemid 26274121)
17. McTiernan A, Martin C, Peck J, Aragaki A, Chlebowski R, Pisano E, Wang C, Brunner R, Johnson K, Manson J et al (2005) Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst 97(18):1366-1376 (Pubitemid 41487804)
18. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, Gillian MA, Walsh BW, Chen C, McTiernan A et al (2008) Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 168(4):370-377; quiz 345
19. Rosenberg L, Einarsdóttir K, Friman E, Wedrén S, Dickman P, Hall P, Magnusson C (2006) Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomark Prev 15(12):2482-2488 (Pubitemid 46048309)
20. Li C, Malone K, Porter P, Weiss N, Tang M, Cushing-Haugen K, Daling J (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254-3263 (Pubitemid 37430078)
21. Ursin G, Tseng C, Paganini-Hill A, Enger S, Wan P, Formenti S, Pike M, Ross R (2002) Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 20(3):699-706 (Pubitemid 34111377)
22. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH et al (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314-4321 (Pubitemid 46621806)
23. Newcomb PA, Egan KM, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ, Willett WC (2008) Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomark Prev 17(4):864-871 (Pubitemid 351536417)
24. Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, Malone KE (2011) Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat 126(3):749-761
25. Nanda K, Bastian L, Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: A systematic review. Am J Obstet Gynecol 186(2):325-334 (Pubitemid 34165456)
26. Wysowski DK, Golden L, Burke L (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 85(1):6-10
27. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risk to Humans (2008: Lyon France) Combined estrogen-progestogen menopausal therapy. In: A review of human carcinogens Part A: pharmaceuticals, vol 100A. World Health Organization, Geneva, pp 249-282